Hydrocision said today that it inked an exclusive worldwide licensing deal to allow Procept BioRobotics to use its pump cartridge technology for urological applications.
Through the agreement, Redwood Shores, Calif.-based Procept BioRobotics will gain the rights to use Boston-based Hydrocision’s pump cartridge technology in its AquaBeam robotic system designed to performed autonomous tissue removal for treating benign prostatic hyperplasia.
“This global agreement with Procept BioRobotics is another significant and strategic step to bring the value of our differentiated technology into new surgical applications affecting millions of people around the world. This is yet another important validation of the value of our proprietary technology,” Hydrocision CEO Alain Tranchemontagne said in a prepared statement.
Procept BioRobotics will provide a one-time, upfront payment for the license, though neither company released details of the terms or payment amount.
“We are pleased to partner with Hydrocision to have immediate access to their unique pumping technology. Having the means to generate the required pressures to deliver high-velocity fluid streams with Hydrocision’s pump cartridge broadens our ability to deliver our proprietary Aquablation technology, which we developed as a core component of Aquablation therapy, a treatment that changes surgery as we know it,” Procept BioRobotics prez & CEO Nikolai Aljuri said in a press release
Hydrocision said that the licensing deal is the second it has inked, having previously granted Smith & Nephew (NYSE:SNN) a license for its FluidJet technology for use in wound care.
Earlier this month, Hydrocision said that it tapped former Smith & Nephew exec Alain Tranchemontagne as its new chief executive officer.
